US20260337241
2026-10-29
Chemistry; metallurgy
C07K14/4703
The patent application outlines innovative materials and methods aimed at rejuvenating aged or senescent cells. The approach involves transducing these cells with a viral vector to express specific proteins (Oct4, Sox2, and Klf4) that facilitate partial cell reprogramming. Additionally, a dominant negative NFκBIA protein is expressed to suppress the senescence-associated secretory phenotype (SASP), which is known to have harmful effects on the tissue microenvironment. These methods have potential applications in treating conditions like progeria syndrome, premature aging, and age-related diseases, offering a novel approach to tissue rejuvenation.
Aging is characterized by complex genomic and epigenomic changes. Research has shown that genetic disruptions in genome maintenance can reduce lifespan, while interventions in pathways like insulin signaling can extend longevity. Other strategies, such as caloric restriction and heterochronic parabiosis, have demonstrated health-span improvements in animal models. Senescent cells, which exhibit a permanent growth arrest and chronic DNA damage signaling, contribute to SASP, leading to inflammation and impaired stem cell function. Understanding the appropriate targets for rejuvenation remains a challenge, as it is unclear how to balance the expansion of young cells with the removal of old ones without compromising tissue integrity.
The invention includes polynucleotides with a senescent-cell specific promoter linked to sequences encoding Oct4, Sox2, and Klf4 proteins. The CDKN2A (p16) promoter is used to ensure specificity to senescent cells. These polynucleotides may also include elements like the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE), internal ribosome entry sites (IRES), and various proteolytic cleavage sites. The inclusion of a dominant-negative NFκBIA protein aims to mitigate SASP effects, enhancing the rejuvenation potential of the method.
The application describes various vectors for delivering the polynucleotides, including viral vectors like adeno-associated viral (AAV) vectors and non-viral vectors such as plasmids. AAV vectors can be of different serotypes, including AAV-DJ, known for its efficiency in gene delivery. The vectors can be incorporated into cells, which may be bacterial, insect, or mammalian, to facilitate the desired genetic modifications. The use of these vectors is critical for ensuring effective delivery and expression of the rejuvenating proteins in target cells.
The described methods and compositions hold significant promise for developing pharmaceutical applications aimed at combating aging and age-related diseases. The invention includes pharmaceutical compositions and kits that incorporate the polynucleotides, vectors, and cells, offering a comprehensive approach to therapy. The potential to rejuvenate tissues and improve health-span without compromising structural integrity represents a major advancement in regenerative medicine, providing new avenues for treating various aging-related conditions.